Secondary Logo

Journal Logo

Critical Care, Trauma, and Resuscitation: Brief-Reports

Elevated Myostatin Levels in Patients with Liver Disease

A Potential Contributor to Skeletal Muscle Wasting

García, Paul S. MD, PhD*; Cabbabe, Amy MD*; Kambadur, Ravi PhD; Nicholas, Gina PhD; Csete, Marie MD, PhD*,§

Author Information
doi: 10.1213/ANE.0b013e3181eac1c9

Loss of skeletal muscle mass is a common complication of end-stage liver disease (ESLD) and contributes to weakness in liver transplant patients. Recent discoveries in the complex regulation of muscle mass have not been extended to the study of ESLD patients. In particular, myostatin, a member of the transforming growth factor β superfamily, is an extremely potent negative regulator of muscle mass.1 In this preliminary study, the first in patients with liver disease, we found that myostatin levels are elevated in patients with ESLD.

METHODS

The study was conducted with Emory IRB approval after informed consent. Nutritional status was evaluated using a widely applied nutritional assessment instrument, the Subjective Global Analysis or SGA.2 Ten milliliters of venous blood was collected from 36 adult patients presenting for liver transplant evaluation and from 6 healthy volunteer controls. Plasma was frozen at −80°C until analysis.

For enzyme-linked immunosensitivity assay (ELISA), recombinant bovine myostatin (used to prepare the standard curve) and rabbit antimyostatin antibody were provided by Drs. Kambadur and Nicholas, who developed the assay. Assays were done in duplicate in 96-well plates (Maxisorp; Nunc, Rochester, NY). Wells were coated with 2 μg/mL myostatin in 0.05 M bicarbonate buffer, pH 9.8. Samples were diluted 1:10 in PBS-T-PVP (0.01 M phosphate-buffered saline with 0.15 M NaCl, 0.05% Tween-20, and 0.1% polyvinylpyrrolidone [PVP], pH 7.4) in a “mixing” plate (Invitrogen, Carlsbad, CA) with antimyostatin (1:50,000), then incubated overnight (4°C).

After 3 washes, ELISA plates were incubated with PBS-T-PVP for 30 minutes and washed with PBS-T. Solution from the mixing plate was transferred to the ELISA plate and incubated for 2 hours, then washed. Goat antirabbit immunoglobulin G secondary conjugated with horseradish peroxidase (1:5000; Dako, Carpinteria, CA) was incubated for 2 hours, followed by PBS-T and PBS washes.

The peroxidase substrate, TMB (3,3′,5,5″-tetramethylbenzidine), was prepared (12.5 mL 0.1 M sodium acetate buffer, pH 5.5 + 125 μL 10 mg/mL TMB in dimethyl sulfoxide), then 125 μL of peroxide (38 μL H2O2 in 2.5 mL dH2O) was added. One hundred microliters of TMB was added to each well, followed by incubation on a shaker for 30 minutes. The reaction was stopped with 50 μL 2 M sulfuric acid/well. Absorbance readings at 450 nm Spectrofluor Plus (Tecan, San Jose, CA) were converted into μg/mL using the standards curve. Because of complex myostatin binding characteristics, these concentrations should be considered estimates but the relative values between groups are reliably captured in the assay.

Data are expressed as mean ± SD. Normally distributed data were compared using Student t tests. Because myostatin levels in the study group were not evenly distributed about a mean, the Kolmogorov-Smirnov statistic was used to obtain P values. The Kolmogorov-Smirnov statistic is used to compare data without constraining either data set to normal (Gaussian) distribution.

RESULTS

Table 1 shows demographic and laboratory data from the study group. Based on the SGA, 53% of these patients were well nourished, 41% moderately malnourished, and 6% severely malnourished.

Table 1
Table 1:
Basic Information on Liver Transplant Candidates (Study Group)

The central finding of this study is shown in Figure 1. Mean myostatin levels in patients with ESLD were 4 times those in normals (mean ± SD): 0.53 ± 0.11 vs 0.13 ± 0.03 μg/mL (P = 0.002). Myostatin levels of the healthy volunteers were tightly clustered, with minimal overlap of the values from healthy versus ESLD groups.

Figure 1
Figure 1:
Myostatin levels in patients with liver disease (D) versus healthy controls. A, Myostatin levels determined by enzyme-linked immunosensitivity assay in patients with end-stage liver disease (ESLD) (left bar) are significantly elevated compared with levels in a group of healthy controls (right bar). B, As a technical control, myostatin levels were measured in ESLD patients with a total bilirubin <1.4 mg/dL (left bar). Mean myostatin levels and distribution were similar to levels in the entire ESLD group. Error bars depict the range.

Because the myostatin assay was colorimetric, it was conceivable that variations in plasma color due to bilirubin could have caused an overestimation of myostatin levels. Therefore, we compared myostatin levels between the control group and a subset of the ESLD group with normal total bilirubin (<1.4 mg/dL). That assay (Fig. 1B) yielded similar results to those obtained from the whole study group, confirming that bilirubin did not significantly affect myostatin measurements.

We tried to determine whether particular diagnoses, laboratory findings, or other factors were significantly associated with high myostatin levels. Men and women had similar levels. Myostatin levels were also not significantly different as a function of diagnosis (comparing hepatitis C/B versus ethanol versus nonalcoholic steatohepatitis versus cryptogenic cirrhosis), but a larger study may be required to dissect such differences. Comparison of laboratory values (Table 1) and physical examination findings (body mass index; triceps skin fold, calf circumference, and SGA data) with myostatin levels did not identify a correlation with a particular subgroup of patients based on nutritional status.

DISCUSSION

Our data suggest that myostatin levels are elevated in patients with ESLD. This finding is likely significant, because in all preclinical settings studied to date, increased myostatin levels contribute to muscle loss although the mechanism of action is not fully understood. Some studies emphasize the antiproliferative effect of myostatin on muscle stem cells.3 Others suggest the mechanism of action is inhibition of protein synthesis independent of stem cells,4 in part through Akt regulation,5 ultimately leading to proteasome-mediated breakdown. In a rat portocaval shunt model, muscle loss was associated with increased myostatin levels, decreased insulin-like growth factor-1 (IGF-1 is a positive regulator of muscle mass), and impaired stem cell function.6

Muscle loss secondary to liver disease is the result of increased muscle protein breakdown and decreased liver and muscle protein synthesis.7 Liver disease is characterized by global hormonal dysregulation because most hormones are metabolized in liver; muscle loss in this setting is attributed to hormonal disruption (particularly insulin resistance) and to cytokines including adipokines. The complex underlying mechanism is acknowledged to be poorly understood, and myostatin is likely only one of many mediators yet to be linked to ESLD-associated muscle wasting.

Increased myostatin levels in patients with ESLD may have implications beyond skeletal muscle. Because myostatin knockout animals have both increased muscle and bone mass,8 myostatin may also be a clinically relevant negative regulator of bone mass. Osteopenia and frank osteoporosis are well-known complications of ESLD.9 Because of the potency of myostatin in causing muscle loss, several therapeutic candidates are in development to block the effects of myostatin in various chronic diseases.10,11 Given the benefit of antimyostatin strategies in preclinical models, our study suggests that antimyostatin therapies deserve further exploration in the setting of ESLD.

AUTHOR CONTRIBUTIONS

PG conducted assays and statistical analyses and helped write the manuscript; AC conducted patient interviews and collected samples; RK and GN provided reagents and expertise for the ELISA; and MC designed and supervised the study, and wrote the IRB protocol and manuscript. All authors contributed to the final manuscript preparation and agree with its contents.

REFERENCES

1. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997;38:83–90
2. Makhija S, Baker J. The Subjective Global Assessment: a review of its use in clinical practice. Nutr Clin Pract 2008;23:405–9
3. McFarlane C, Hennebry A, Thomas M, Plummer E, Ling N, Sharma M, Kambadur R. Myostatin signals through Pax7 to regulate satellite cell self-renewal. Exp Cell Res 2008;314:317–29
4. Amthor H, Otto A, Vulin A, Rochat A, Dumonceaux J, Garcia L, Mouisel E, Hourdé C, Macharia R, Friedrichs M, Relaix F, Zammit PS, Matsakas A, Patel K, Partridge T. Muscle hypertrophy driven by myostatin blockade does not require stem/precursor-cell activity. Proc Natl Acad Sci USA 2009; 106:7479–84
5. Morissette MR, Cook SA, Buranasombati C, Rosenberg MA, Rosenzweig A. Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt. Am J Physiol Cell Physiol 2009; 297:C1124–32
6. Dasarathy S, Dodig M, Muc SM, Kalhan SC, McCullough AJ. Skeletal muscle atrophy is associated with an increased expression of myostatin and impaired satellite cell function in the portacaval anastamosis rat. Am J Physiol Gastrointest Liver Physiol 2004;287:G1124–30
7. Tessari P. Protein metabolism in liver cirrhosis: from albumin to muscle myofibrils. Curr Opin Clin Nutr Metab Care 2003;6:79–85
8. Hamrick MW. Increased bone mineral density in the femora of GDF8 knockout mice. Anat Rec A Discov Mol Cell Evol Biol 2003;272:388–91
9. Guichelaar MM, Kendall R, Malinchoc M, Hay JE. Bone mineral density before and after OLT: long-term follow-up and predictive factors. Liver Transpl 2006;12:1390–402
10. Wagner KR, Fleckenstein JL, Amato AA, Barohn RJ, Bushby K, Escolar DM, Flanigan KM, Pestronk A, Tawil R, Wolfe GI, Eagle M, Florence JM, King WM, Pandya S, Straub V, Juneau P, Meyers K, Csimma C, Araujo T, Allen R, Parsons SA, Wozney JM, Lavallie ER, Mendell JR. A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 2008;63:561–71
11. Tsuchida K. Targeting myostatin for therapies against muscle-wasting disorders. Curr Opin Drug Discov Devel 2008;11:487–94
© 2010 International Anesthesia Research Society